Evidence map›Paper›PMID 27514750›Full record

ArticleCirculation. Heart failure2016

Implications of Using Different Definitions on Outcomes in Worsening Heart Failure.

Jacob P Kelly, Lauren B Cooper, Dianne Gallup, Kevin J Anstrom, Horng H Chen, Margaret M Redfield, Christopher M O'Connor, Robert J Mentz, Adrian F Hernanadez, G Michael Felker

2 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Heart failure, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00577135 phase3completednot on this map

Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)

TypeinterventionalSponsorDuke UniversityRan2008 to 2010Enrolled308ConditionsHeart FailureArmsFurosemide-Q12 hour bolus, Furosemide-Continuous Infusion, Furosemide-Low Intensification, Furosemide-High Intensification
NCT01132846 phase2completednot on this map

Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network ROSE Study

TypeinterventionalSponsorDuke UniversityRan2010 to 2013Enrolled360ConditionsAcute Heart FailureArmsPlacebo, Nesiritide, Dopamine
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jacob P KellyFrom the Duke Clinical Research Institute, Duke Medicine, Durham, NC (J.P.K., L.B.C., D.G., K.J.A.,C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC (J.P.K., L.B.C., C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (H.H.C., M.M.R.); and Inova Heart and Vascular Institute, Falls Church, VA (C.M.O'C.). Jacob.kelly@duke.edu.
Lauren B CooperFrom the Duke Clinical Research Institute, Duke Medicine, Durham, NC (J.P.K., L.B.C., D.G., K.J.A.,C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC (J.P.K., L.B.C., C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (H.H.C., M.M.R.); and Inova Heart and Vascular Institute, Falls Church, VA (C.M.O'C.).
Dianne GallupFrom the Duke Clinical Research Institute, Duke Medicine, Durham, NC (J.P.K., L.B.C., D.G., K.J.A.,C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC (J.P.K., L.B.C., C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (H.H.C., M.M.R.); and Inova Heart and Vascular Institute, Falls Church, VA (C.M.O'C.).
Kevin J AnstromFrom the Duke Clinical Research Institute, Duke Medicine, Durham, NC (J.P.K., L.B.C., D.G., K.J.A.,C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC (J.P.K., L.B.C., C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (H.H.C., M.M.R.); and Inova Heart and Vascular Institute, Falls Church, VA (C.M.O'C.).
Horng H ChenFrom the Duke Clinical Research Institute, Duke Medicine, Durham, NC (J.P.K., L.B.C., D.G., K.J.A.,C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC (J.P.K., L.B.C., C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (H.H.C., M.M.R.); and Inova Heart and Vascular Institute, Falls Church, VA (C.M.O'C.).
Margaret M RedfieldFrom the Duke Clinical Research Institute, Duke Medicine, Durham, NC (J.P.K., L.B.C., D.G., K.J.A.,C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC (J.P.K., L.B.C., C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (H.H.C., M.M.R.); and Inova Heart and Vascular Institute, Falls Church, VA (C.M.O'C.).
Christopher M O'ConnorFrom the Duke Clinical Research Institute, Duke Medicine, Durham, NC (J.P.K., L.B.C., D.G., K.J.A.,C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC (J.P.K., L.B.C., C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (H.H.C., M.M.R.); and Inova Heart and Vascular Institute, Falls Church, VA (C.M.O'C.).
Robert J MentzFrom the Duke Clinical Research Institute, Duke Medicine, Durham, NC (J.P.K., L.B.C., D.G., K.J.A.,C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC (J.P.K., L.B.C., C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (H.H.C., M.M.R.); and Inova Heart and Vascular Institute, Falls Church, VA (C.M.O'C.).
Adrian F HernanadezFrom the Duke Clinical Research Institute, Duke Medicine, Durham, NC (J.P.K., L.B.C., D.G., K.J.A.,C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC (J.P.K., L.B.C., C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (H.H.C., M.M.R.); and Inova Heart and Vascular Institute, Falls Church, VA (C.M.O'C.).
G Michael FelkerFrom the Duke Clinical Research Institute, Duke Medicine, Durham, NC (J.P.K., L.B.C., D.G., K.J.A.,C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC (J.P.K., L.B.C., C.M.O'C., R.J.M., A.F.H., M.F.); Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (H.H.C., M.M.R.); and Inova Heart and Vascular Institute, Falls Church, VA (C.M.O'C.).
Alaska Heart and Vascular Institute · USDuke University · USMayo Clinic · US

Funding

MULTIDISCIPLINARY HEART &VASCULAR DISEASEST32HL007101 · NHLBI · DUKE UNIVERSITY · PI FREEDMAN, NEIL J. · 1985 to 2020
$9.8M
Postdoctoral Training in Cardiovascular Clinical ResearchT32HL069749 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2003 to 2023
$6.7M
Heart Failure Clinical Research Network Regional Clinical Center (U10)U10HL110312 · NHLBI · DUKE UNIVERSITY · PI FELKER, GARY M · 2012 to 2018
$3.5M
NHLBI NIH HHS T32 HL007101NHLBI NIH HHS T32 HL069749NHLBI NIH HHS U10 HL110312
6 · The paper itself

Abstract

backgroundIn-hospital worsening heart failure (WHF) is an important event that has inconsistent definitions used across trials. We used data from 2 acute heart failure (HF) trials from the National Institutes of Health HF Network, DOSE (Diuretic Optimization Strategies Evaluation) and ROSE (Renal Optimization Strategies), to understand event rates associated with different WHF definitions. METHODS AND

resultsWe pooled data from 668 patients in DOSE and ROSE and assessed the relationship between WHF and the composite end point of rehospitalization, emergency room visits for HF, and mortality through 60 days. We also assessed for a differential relationship between the timing of WHF development and outcomes. The overall incidence of WHF was 14.6% (24.1% in DOSE, 6.3% in ROSE, and 5.0% in DOSE using the ROSE definition). WHF was associated with an increase in the composite end point (hazard ratio [HR], 1.64; 95% confidence interval [CI], 1.11-2.42; P=0.01). However, the association between WHF and outcomes was significantly stronger in ROSE than in DOSE (HR, 2.67; 95% CI, 1.45-4.91; P<0.01 and HR, 1.28; 95% CI, 0.79-2.08; P=0.31, respectively). Development of WHF between baseline to 24 hours compared with 24 to 48 hours or 48 to 72 hours demonstrated a trend toward improved outcomes (HR, 0.49; 95% CI, 0.21-1.17; P=0.11 and HR, 0.45; 95% CI, 0.20-1.04; P=0.06, respectively).

conclusionsA WHF definition that excluded the intensification of diuretics resulted in a lower event rate but a stronger association with outcomes. These data support the need for continued efforts to standardize WHF definitions in clinical trials. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifiers: NCT00577135 (DOSE) and NCT01132846 (ROSE).

Indexed as

Terminology as TopicAcute DiseaseAgedCardiovascular AgentsDisease ProgressionDiureticsEmergency Service, HospitalFemaleHeart FailureHospitalizationHumansIncidenceMaleMiddle AgedPatient ReadmissionPredictive Value of TestsCardiovascular AgentsDiureticsdiureticsheart failurehospitalizationoutcome assessment (health care)

Identifiers

PMID27514750
PMCPMC5139347
OpenAlexW2517757431

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.